IC7 Stock Overview
Develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ICU Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$160.00 |
| 52 Week High | US$170.00 |
| 52 Week Low | US$76.50 |
| Beta | 0.66 |
| 11 Month Change | -0.62% |
| 3 Month Change | 10.34% |
| 1 Year Change | 109.15% |
| 33 Year Change | -23.08% |
| 5 Year Change | -5.33% |
| Change since IPO | 500.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| IC7 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.3% | 0.5% | 0.2% |
| 1Y | 109.2% | -6.8% | 8.5% |
Return vs Industry: IC7 exceeded the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: IC7 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| IC7 volatility | |
|---|---|
| IC7 Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: IC7 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: IC7's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 14,000 | Vivek Jain | www.icumed.com |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options.
ICU Medical, Inc. Fundamentals Summary
| IC7 fundamental statistics | |
|---|---|
| Market cap | €3.96b |
| Earnings (TTM) | -€106.60m |
| Revenue (TTM) | €2.25b |
1.8x
P/S Ratio-37.2x
P/E RatioIs IC7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IC7 income statement (TTM) | |
|---|---|
| Revenue | US$2.34b |
| Cost of Revenue | US$1.57b |
| Gross Profit | US$769.11m |
| Other Expenses | US$880.12m |
| Earnings | -US$111.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.53 |
| Gross Margin | 32.87% |
| Net Profit Margin | -4.74% |
| Debt/Equity Ratio | 77.8% |
How did IC7 perform over the long term?
See historical performance and comparison